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The randomized control trial has long been held as the gold standard in the scientific community when testing hypotheses. In medicine, when introducing new drugs, this remains the standard to which the medical community holds drugs to. However, randomized control trials pose an incredible expense in terms of research cost and liability. This expense leads to increased developmental costs and more costs incurred further down the healthcare chain.
          The rise in research and development costs with regard to new drugs is staggering. From 1975 to 2005, the cost rose from 100 million dollars to over ten times that amount to 1.3 billion dollars​[1]​. 

Figure 1. Average cost to develop a new drug

Much of the costs incurred from research and development come in the clinical trials of the drug, namely Phase III. Some major cost drivers in Phase III are the length and complexity of the trials themselves. In a span of six years, from 1999 to 2005, the average length of a clinical trial in phase III increase by 70%​[2]​. In addition to that significant increase in length, there are other significant increases in cost drivers. In terms of complexity of the trials, the average number of routine procedures per trial increased by 65% and the clinical work staff had its work burden increased by 67%. In addition to these increased cost drivers, the increased recruitment barriers and more stringent test protocols have led to 21% fewer volunteers and 30% less enrollees finishing the entire course of the trial​[3]​.


Table 1. Changes in Clinical Trials: Resources, Length, and Participation


The Food and Drug Administration (FDA), the agency in charge of drug testing, is well aware of rising costs of clinical trials. In an effort to stem the tide of these rising costs, the FDA has tried to implement new policies. These policies include allowing remote monitoring of Phase II clinical trials as well as computer modeling in device trials. However, while the purpose of these policies is to reduce the cost of clinical trials, there have not been significant returns. This paper proposes to use an advanced computer model such as Archimedes to be used in Phase III drug testing. Archimedes can serve to model populations, but ultimately, the goal is to use Archimedes to model the control group in Phase III testing to serve as a key component in reducing the cost of clinical trials.
2.0 	Background to clinical drug testing
When looking at clinical trials, the distribution of studies revealed that over 50% of the study and intervention types were focused on drug or biological interventions. As previously noted, this is an extremely significant cost presented to pharmaceutical companies.
Table 2. Types of Clinical Trials













Clinical testing for drugs involves three distinct phases. After passing the required laboratory and animal trials, drugs enter human testing. Phase I includes the recruitment of a maximum of 100 patients for the initial phase of testing for safety and efficacy. Phase II, which includes a recruitment of up to 300 patients, and is an extension of that initial test for safety and efficacy. Phase III is the largest extension of this testing, requiring the recruitment of thousands of patients who are treated with the drug that is being tested as well as a placebo, which in most cases is the current treatment protocol for the aforementioned disease. It is in this phase, both due to the large amount of recruits and the liability of the drug company with widespread testing where much of the cost of drug development lie.
In Phase III testing drug companies spend vast amounts of money, up to 90% of the total research and development money, for comprehensive testing​[4]​. The reason for the large number of recruited patients is the necessity for statistical rigor in the testing. As previously noted, the FDA is keenly aware of the obstacles and problems in this phase of the process and has put forth some solutions to address this situation. However, Phase III testing as a development cost is an economic burden that de-incentivizes pharmaceutical companies to innovate and puts an undue emphasis on the ability for a new drug to be able pass the rigors of the FDA testing protocol. The cost of clinical trials has risen by 12% annually​[5]​ in past years. This has caused the pharmaceutical industry to adopt risk-averse behavior, leading to increased costs in procedural issues and the business of clinical testing has spawned an entire industry around regulatory issues. As such, this paper proposes a new methodology that could possibly be used to decrease the sizable costs of Phase III trials by using a computer model called Archimedes to accurately simulate the trial results of the control group, decreasing costs for recruitment, monitoring, and medical care for the trial.


3.0 	The archimedes model
Dr. David Eddy and his team has been developing the Archimedes Model for the past 15 years. The Archimedes model is a complex set of equations which has been developed to simulate the effects of multiple organ systems​[6]​. Over years of refinement, the system has demonstrated a high degree of accuracy at modeling the effects of different drugs and interventions for cardio metabolic disease. The advantage of Archimedes over other computer models is that individual factors in Archimedes can be adjusted such as age, disease state, and race, among many others. While other models may be able to adjust for these factors statistically after the simulation has been run, Archimedes is able to build these factors into the actual mechanics of the model which yields a more accurate and complex simulation. Archimedes has been tested many times and has been held to a high rate of veracity. The model is also constantly updated as it attempts to incorporate all available medical knowledge based on previous trials and recent literature. In addition the strength of the using this advanced model to simulate the trials is that the control group is not limited to a specific number and makeup. In fact, the control group, if using a computer model, can encapsulate any makeup that the testing so chooses. Using a computer model like Archimedes also yields another utility which is the ability for the control group to match the clinical makeup of the intervention group.
Archimedes is uniquely suited to the modeling of clinical trials. From its conception it was built differently from other models. The model is composed of two separate components, the physiological component and the model of care processes. In the context of using a computer model to supplement clinical trials, the physiological component of the Archimedes model will be the main focus. In dealing with the physiology, the Archimedes model has several discrete components that improve its viability as a model for clinical trials. In Archimedes, each single individual is designated as an agent. Each agent has its own physiology, which is denoted as features. Organ systems are represented by multiple features that have their own unique variables which mimic the effect of the human body. Each feature responds to a range of anatomical and biological variables. Within each feature, there is a value assigned, which corresponds to a specific measurable. All of this is programmed and executed in real-time as to plot the trajectory of a particular value and its effect on the features and the agent as a whole. 
When building Archimedes, the designers took into mind modeling that would fit for cardio metabolic disease. When crafting the Archimedes model to handle diabetes, between 10 and 30 equations were needed to craft the physiological response to represent diabetes​[7]​. When writing these equations, external data was used to inform the time course of the feature and produce biomarkers of the disease. From these biomarkers, conclusions about the disease state can be reached. There were rare instances where a trial provides information which greatly advances the bounds of the model, and the trial contributed two or three pieces of information.  However, Archimedes does not simply use the results of a trial to craft an equation where the equation is created to fit the trial which it is based on. As previously stated, the model already consists of differential equations simulating physiological systems. When using trial data to bolster the already powerful model, the new equations are added to the model on a permanent basis, which both increases the complexity and ability of the model to more accurately model the human body. In addition, the parameters of an equation are never changed to fit particular trials​[8]​. Previous tests done with Archimedes are re-run with the new equations to see if the new information does not impair the accuracy of the model with regards to previous simulations. Archimedes as a model is brilliant in the fact that it is ever growing in complexity and adapts to the current information in a way that ensures fidelity to previous held standards but ever accommodating of new information. The main drive of these trials was to develop Archimedes to further evaluate the complications that arise in conjunction with diabetes.
In addition to the aforementioned aspects, the model also can account for risk factors such as family history, gender, age, as well as others. While these aspects of Archimedes are important, the ability to simulate observable changes in health through tests is what makes Archimedes a prime candidate for replicating clinical trials. The ability for a model that accurately simulates the observability and the utility of tests in the clinical setting is vital to creating a viable candidate for replacing the control aspect of the clinical trial. Again the use of the model would not be to simulate the effect that the new drug would have on the human body, but a way for the investigators to replace the placebo or standard medical protocols already used to treat the disease in question.
As such, the Archimedes model may be able to address these burgeoning issues in drug development cost. In using Archimedes to simulate the control arm of randomized control trials, the costs of Phase III drug testing could be lowered by a significant percentage, reducing costs passed on to the healthcare systems and allowing pharmaceutical companies to take more risks with regards to drug research and development. By applying the strength of Archimedes, the control group can essentially be simulated. While the obvious movement is to migrate all drug testing to this model, it can be argued that with a new drug, there are simply mechanisms and side effects that we have not accounted for, and therefore, still must be tested on live subjects. However, the control groups that need to be recruited can be treated as an unnecessary expense. The costs that would be saved from patient care on the control group, whose information should already be built into the Archimedes model would serve to provide relevant information while eliminating the need to perform control trials on live patients. There are two possible ways that this can provide a benefit to the current model of Phase Three testing. The first, as previously stated, is the ability to reduce cost by eliminating the need for a live patient control group by substituting the simulated model results. The second, if one decides to keep the costs as they are, would be the recruitment of more patients into the experimental group, which may yield more substantive results, thus, maintaining costs, but providing more detailed information on the drug. In either circumstance, using the Archimedes model as the basis for the control trials yields an improvement on the current model of Phase Three testing, either by virtue of increased cost-efficiency or improved and more detailed results on the drug being tested.
	The possibilities offered by Archimedes are extremely enticing, however, if Archimedes is to be used in a rigorous testing process that plays a major role in the clinical trials, the model needs to be validated and proven to have no statistically significant differences between real world trials and simulations.
4.0	 validation of the archimedes model
The validation of Archimedes took place in a series of experiments. The most basic of these experimental setups consisted of inputting the data used to construct the model and verifying if the model correctly processed the data. This type of verification is mainly used for debugging the model and does not yield any substantial support for the model’s use in supplementing clinical trials. However, the validation that provides the most evidence is the ability for Archimedes to simulate the course of a trial using an existing study and using the outcome of the simulation to see if Archimedes simulated statistically matching results.  If Archimedes meets these criteria, then the exploration for the approved use of Archimedes to model certain aspects of randomized control trials has strong scientific support. In this specific instance with the potential reduction in research costs with regards to chronic disease, the focus will be the formulation and validation of Archimedes with regards to diabetes.
The creators of the Archimedes model attempted to validate the model in testing it starting with 18 separate trials​[9]​ which has increased over time. 10 of these trials were directly related to diabetes with another eight trials chosen for their representation of coronary artery disease with relation to diabetes. From these 18 trials, Archimedes was run to model cohorts from ‘birth’ to their disease state. Running the simulations for the chosen trials created diverse and distinct populations which protected the model from a narrow perspective.
Once the trials were simulated, the validity of the model had to ascertained. In targeting the specific outcomes to be compared, outcomes that were highly dependent on process of care and not disease factors were avoided as outcome measures. This was done because the focus of the Archimedes model was the validation as a physiological model. While process of care can be modeled in Archimedes, the outcomes that are attached to it would yield widely varying results which are not necessarily indicative of its accuracy as a model for diabetes and its complications. However, some factors such as drug compliance were factored into these results as their inclusion was vital to the veracity of the results of the trials. When validating the model, the team used an extremely conservative approach which was biased against Archimedes. As the typical enrollment into clinical trials is staggered, the reported data in the final year of the trial is usually an incredibly small size compared to the number of participants in the trial. In order to account for this difference where the Archimedes model can follow each member of its simulated trial to the end, the team took the last observed data point for the real world trials which allowed them to create a trial that could be compared to the simulation​[10]​. As previously stated, this created a situation where the simulation was placed in an unfavorable situation when trying to model statistical significance due to the fact that it underestimates the variation that affects the end result in the clinical trial.
For the validation, the arms of the trial were defined to be different at a statistically significant measure at the p = 0.05 level. 74 validation trials were performed to measure each outcome and each arm of the 18 clinical trials that were studied. These trials were composed of both dependent and independent trials. In certain instances, data from the trial may have been used in scripting Archimedes, informing the model of certain changes in biomarkers. However, the outcome data was not used, and in the independent trials, no data in any arm was used in the model. Of these 74 validation trials, 71 of them yielded statistically matching results, which is a 95.95% correlation. 


Figure 2. Comparison of model and trial: fraction of patients having myocardial infarctions in UKPDS
Source: Eddy DM, Schlessinger L, “Validation of the Archimedes diabetes model.” Diabetes Care 26:3102-3110, 2003

Of the three validation trials that were not matching, those trials were not used in the construction of the Archimedes model. One of the trials that was not statistically matching barely reached a level of statistical significance on its own and if one adjusted for this, the actual accuracy for modeling the effectiveness of the treatment was fairly high. The correlation coefficient for all 74 exercises is r = 0.99. More importantly, for the 10 trials that were not used to build the model, the correlation coefficient is also r = 0.99, this including the 3 trials that did not statistically match​[11]​. While obviously there was not a complete statistical match on the 74 validation trials run, the degree of similarity should prove as a foundation for advocating for more advanced application of Archimedes in terms of clinical trials. This validation study lends credibility to the claim that Archimedes has a credible standing as a biological model of a human system. 
In running the 74 validation trials, the value of the trials were not simply an exercise in redundancy, but an exercise in strenuously testing the various aspects of the model. The wide spectrum of complications and biological variables that deal with diabetes covered in these 18 trials tested the ability of the Archimedes model to serve as an advanced biological model. Each validation tested the validity of different parts of the model while also testing the fidelity of the other biological equations of the model. In running these validation exercises, Archimedes not only proves that it can model deep biological processes, but that it can also incorporate new knowledge into its already impressive physiological model with a high degree of accuracy.
With all of the benefits to using Archimedes as a model for clinical trials, there should be word of caution. While Archimedes is a powerful physiological tool, there are limitations to the model. Archimedes can be used to simulate non-biological processes; there is an inherent weakness when it did not simulate clinical procedure that has no direct biological response. Archimedes did not account for patient and physician behavior which may impact the biological status of the patient in these validations in the clinical setting. However, Archimedes does have the tools available to do such an evaluation, but the parameters of the test did not include this in the validation tests.
When looking at the validation trials that failed to match the clinical trial results, one would like to clarify that the model predicted the absolute effect of the drug, but failed to model the background instances of a complication regarding diabetes. This misrepresentation of the complication could possibly be due to a risk factor that was either undocumented or measured. This lack of effective data that could be an input into the model is a possible risk that comes with dealing the populations in clinical trials.


5.0 	the potential use of archimedes in clinical trials
The application to using Archimedes for clinical drug testing in the current market makes fiscal and scientific sense. With nearly a third of Americans considered obese, both the market and the need for drugs addressing obesity and diabetes are increasing. As these are both chronic conditions, the testing for these drugs often take significantly longer than their counterparts which treat acute illnesses. The logic is simple: with chronic conditions it simply takes a longer period of time for the effects of a drug to be evident. This leads to prolonged trial times which may lead to inconclusive results, or perhaps lead to another round of testing, which would again be subjected to extended testing due to the chronic nature of the diseases​[12]​. The benefit of using a computer model such as Archimedes for clinical trial testing is very clear. The time could possibly be shortened to push the drug to market. Archimedes could even possibly be used as a preliminary test to key investigators into the changes that could be observed. This could streamline the clinical trial process as it could focus the research and identify the key changes that would be clinically relevant.
Using a computer model to denote and possibly determine possible effects of the drug would be magnified in drugs meant to treat chronic conditions. As previously stated, the challenge of clinical trials is the relatively long test period of these drugs. In addition, the effects of these may be relatively discreet compared to drugs targeted for acute illnesses. The challenge of finding the effects from the these drugs may be compounded due to the fact that these drugs may simply reduce the severity of the condition would be harder to assess and more significant trials would be undertaken with regards to a statistically significant result showing a difference in quality. Seeing potential pre-cursors and indicators with regards to clinical difference could potential help tailor clinical trials to look for certain indicators that were previously noted with the computer model. This could potentially yield more streamlined results which would reduce research and development costs.
When looking at cost, it is hard to pinpoint the actual effect that Archimedes may have on lowering the costs of Phase III clinical trials.  Due to the opacity of the exact finances involved in individual aspects of clinical trials, arriving at an exact estimate for certain cost points is incredibly difficult. However, by approximating a two-way sensitivity analysis, one can begin to form a preliminary estimate at the possible impact of using Archimedes to model the control group of a Phase III clinical trial. As previously noted, Phase III trials can take up to 90% of research and development costs. Using this percentage as the upper-bound and 60% as the lower bound, one arm of the sensitivity test could be set. The other arm would be the percentage in reduction that the Archimedes model could provide, setting a conservative estimate at 10% and the upper bound at an optimistic 40%. 

Figure 3. Projected savings using Archimedes to supplement Phase III trials

Using the 2005 cost estimate for the cost of a new drug at $1.3 billion dollars, a conservative estimate of the savings using Archimedes to model the control arm of can save $78 million dollars with an upper bound limit of $468 million dollars. While the conservative estimate may only be a 4% decrease in total cost of development, $78 million dollars is still an extremely significant amount of money and the percentage decrease can be the first time in flat-lining the continual rise in development cost for drugs.
These cost projections and trials are currently tied to the assumption that running a randomized control trial with Archimedes serving as the control would yield identical results. While these validation trials do tend to support a favorable few on Archimedes, one must also analyze the possible ramifications if Archimedes is not a carbon copy of the control or placebo group.
For an exploratory approach, suppose that there are 200 new drugs and 50% of the drugs perform better than current treatment and 50% of the drugs perform worse than the current treatment. With no testing, using these new drugs would yield 50% of the population being worse off than they were with 50% showing improvement over the current treatment. Suppose that the budget for traditional randomized control trials can only accommodate testing for 100 drugs. If this testing is applied, the 100 drugs that are not tested would still be split 50/50 yielding 25% of those treated with the untested drug to be efficacious and 25% to be worse off. Assuming the standard p = .05 for randomized control trials, that would mean 95% of the drugs tested would be identified correctly, with 5% of the drugs tested to be incorrectly identified, 2.5%, or in this case, rounded up to 3 drugs being incorrectly identified for both improving the level of care of lowering the level of care. However, using Archimedes as the control group in a randomized control trial could be more cost effective. If we assume that Archimedes provides cost savings that could apply to cover all randomized control trials while adhering to p = .05, then only 5% out of the 200 drugs would be misrepresented by the trials, with half of that being deleterious to the population, at 5 drugs, only 2.5% of the population. However, even if Archimedes was not an exact duplicate of the control group and served to increase the p-value of the randomized control trial, the p-value would have to be .525 to breakeven with the 100 tests done by traditional randomized control trials. 
Table 3. Results of Hypothetical Clinical Trials
	No Trials	RCT (p = .05)	RCT w/ Archimedes (p = .05)	RCT w/ Archimedes (p = .525)
Number of Drugs Tested	0 (0%)	100 (50%)	200 (100%)	200 (100%)




Drugs that could be used with deleterious effects	100 (50%)	53 (26.5%)	5 (2.5%)	53 (26.5%)
These numbers take into account that drugs tested but were found to be less effective would not be used, but untested drugs could still be used. Likewise, drugs tested, but with lack of statistical power, could be misidentified and used to deleterious effects. While this is very crude example, one can begin to see the relevance the impact that Archimedes could have with randomized control trials. It is extremely idealistic to believe that a traditional randomized control trial would have the same p-value as a trial using Archimedes as the control. However, from this example, one will note the extremely high p-value that would be needed to essentially match the limited scope of the traditional randomized control trial due to budgetary concerns. The idea that is to be examined is to what extent is a less accurate test viable when the trade-off is more of these tests being done. The cost savings provided by using Archimedes would lend itself to more trials being performed. While they may be of lower quality, the trials involving Archimedes should not be at such a large statistical disadvantage as the validations in this paper show.

5.0 	Conclusion
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